Last reviewed · How we verify
Low dose ASA
Low-dose aspirin inhibits platelet cyclooxygenase to reduce thromboxane A2 production, preventing platelet aggregation and clot formation.
Low-dose aspirin inhibits platelet cyclooxygenase to reduce thromboxane A2 production, preventing platelet aggregation and clot formation. Used for Primary prevention of cardiovascular events, Secondary prevention of myocardial infarction and stroke, Atrial fibrillation for stroke prevention.
At a glance
| Generic name | Low dose ASA |
|---|---|
| Also known as | Low-dose aspirin |
| Sponsor | University of Pennsylvania |
| Drug class | Antiplatelet agent / NSAID |
| Target | Cyclooxygenase-1 (COX-1) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Aspirin irreversibly acetylates cyclooxygenase-1 (COX-1) in platelets, blocking thromboxane A2 synthesis. This reduces platelet activation and aggregation, thereby decreasing thrombotic events. Low-dose formulations (typically 75–325 mg daily) preferentially affect platelet function while minimizing gastrointestinal side effects associated with higher doses.
Approved indications
- Primary prevention of cardiovascular events
- Secondary prevention of myocardial infarction and stroke
- Atrial fibrillation for stroke prevention
Common side effects
- Gastrointestinal bleeding
- Dyspepsia
- Bruising/minor bleeding
- Hemorrhagic stroke
Key clinical trials
- Screening and Multiple Intervention on Lung Epidemics (PHASE2)
- Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- Blood Flow Restricted Resistance Exercises Versus Low Level Laser on Cardiac Functions in Patients With Chronic Heart Failure (NA)
- Aspirin to Target Arterial Events in Chronic Kidney Disease (PHASE3)
- AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms (PHASE3)
- Adjuvant Low Dose Aspirin in Colorectal Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low dose ASA CI brief — competitive landscape report
- Low dose ASA updates RSS · CI watch RSS
- University of Pennsylvania portfolio CI